

SUPPLEMENTAL STATEMENT – Afluria[®] Tetra

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

Canadian Immunization Guide Chapter on
Influenza and Statement on Seasonal Influenza
Vaccine for 2018–2019

PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH



Public Health
Agency of Canada

Agence de la santé
publique du Canada

Canada

**TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP,
INNOVATION AND ACTION IN PUBLIC HEALTH.**

—Public Health Agency of Canada

Également disponible en français sous le titre :

Déclaration supplémentaire - Afluria^{MD} Tetra

Une déclaration d'un comité consultatif (DCC)

Comité consultatif national de l'immunisation (CCNI)

Chapitre sur la grippe du Guide canadien d'immunisation et Déclaration sur la vaccination antigrippale pour la saison 2018-2019

This publication can be made available in alternative formats upon request.

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2018

Publication date: November 2018

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. However, multiple copy reproduction of this publication in whole or in part for purposes of resale or redistribution requires the prior written permission from the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5 or copyright.droitdauteur@pwgsc.gc.ca.

Cat.: HP37-25E-PDF

ISBN: 2371-5375

Pub.: 180566

PREAMBLE

The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.

In addition to burden of disease and vaccine characteristics, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing evidence-based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels.

The additional factors to be considered by NACI include: economics, ethics, equity, feasibility, and acceptability. Over the coming years NACI will be refining methodological approaches to include these factors. Not all NACI Statements will require in-depth analyses of all programmatic factors. As NACI works towards full implementation of the expanded mandate, select Statements will include varying degrees of programmatic analyses for public health programs.

PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

TABLE OF CONTENTS

Summary of the Information Contained in this NACI Supplemental Statement	4
I. Introduction	5
II. Methods	5
III. Vaccine	6
IV. Recommendations	9
Tables	10
List of Abbreviations	21
Acknowledgments	22
References	23
Appendix A: Prisma Flow Diagram	25

SUMMARY OF THE INFORMATION CONTAINED IN THIS NACI SUPPLEMENTAL STATEMENT

The following highlights key information for immunization providers. Please refer to the remainder of this supplemental statement for details.

1. What

Afluria® Tetra is a split virus quadrivalent inactivated influenza vaccine that has recently been authorized for use in Canada.

2. Who

This supplemental statement addresses the annual influenza vaccination of adults and children who do not have contraindications for the influenza vaccine.

3. How

Afluria® Tetra may be considered among the quadrivalent influenza vaccines offered to adults and children ≥ 5 years of age for their annual influenza vaccination.

4. Why

Afluria® Tetra is considered safe and immunogenic in adults and children ≥ 5 years of age, and has a comparable safety and immunogenicity profile to already licensed influenza vaccines.

I. INTRODUCTION

Influenza is a viral infection that is estimated to cause 12,200 hospitalizations⁽¹⁾ and 3,500 deaths⁽²⁾ in Canada annually. Each year, NACI publishes a statement on seasonal influenza vaccines, which contains recommendations on the use of influenza vaccines for the upcoming influenza season. Influenza in humans is caused by two main types of influenza virus: A, which is classified into subtypes based on haemagglutinin (HA) and neuraminidase surface proteins, and B, which consists of two antigenically distinct lineages, B/Yamagata and B/Victoria. Seasonal influenza vaccines are either trivalent or quadrivalent formulations. Trivalent influenza vaccines contain two influenza A and one influenza B strain, and quadrivalent influenza vaccines contain the three strains included in trivalent vaccines and an additional influenza B strain from the other lineage of influenza B.

Afluria® Tetra (Seqirus Pty Ltd) is a split virus quadrivalent inactivated influenza vaccine (QIV) that was authorized for use in Canada in adults and children 5 years of age and older in February 2018. This authorization triggered the need for a supplemental statement as NACI has not previously made a recommendation on the use of this vaccine in any population. Afluria® Tetra is the quadrivalent formulation of Afluria® (Seqirus Pty Ltd), a trivalent split virus inactivated influenza vaccine (TIV). The manufacturer of Afluria® (trivalent) has not sought approval for use in Canada at the time of publication of this supplemental statement.

Guidance Objective:

The objective of this advisory committee supplemental statement is to review the efficacy, effectiveness, immunogenicity, and safety evidence available for Afluria® Tetra and to provide guidance on its use in adults and children.

II. METHODS

The NACI Influenza Working Group (IWG) decided on a review protocol a priori that included review questions, search strategy, inclusion and exclusion criteria, and quality assessment. The IWG developed the following research question and accompanying PICO to guide the review:

- What are the vaccine efficacy, effectiveness, immunogenicity, and safety of Afluria® Tetra in adults and children?

P (Population):	Adults and children (≥6 months)
I (intervention):	Afluria® Tetra or Afluria® (1.5% sodium taurodeoxycholate [TDOC] formulation)
C (comparator):	Comparator TIV, comparator QIV, placebo, or no comparator
O (outcome):	Efficacy, effectiveness, immunogenicity, safety

Since Afluria® Tetra is a new vaccine, no post-marketing studies have been completed to date. To supplement the evidence for Afluria® Tetra, the IWG decided to include any studies that assessed the efficacy, effectiveness, immunogenicity, and safety of Afluria® (the trivalent formulation) that is manufactured using the same manufacturing process as Afluria® Tetra. The manufacturing process for Afluria® Tetra involves the use of 1.5% TDOC as a splitting agent. Prior to the 2017–2018 Northern Hemisphere season, the manufacturing process for Afluria®

used $\leq 1.5\%$ TDOC. The use of 1.5% TDOC as a splitting agent was incorporated in the manufacturing process for Afluria® after a safety signal in the 2010 Southern Hemisphere influenza season in Australia showed that Afluria® made with $\leq 1.5\%$ of TDOC was associated with an increased rate of fever and febrile seizures in children < 5 years of age⁽³⁾. This issue is further discussed in Section III.4.2 of this document.

In addition, the IWG decided to include studies completed in children 6 months of age and older to capture the entirety of available evidence in children, despite the manufacturer's not seeking an indication in this age group at the time of publication of this supplemental statement.

The search strategy was developed based on the research question and PICO in conjunction with a librarian from the Health Library of Health Canada and PHAC (search strategy available upon request). Two reviewers independently screened the titles and abstracts of records retrieved from the search and eligible full-texts for inclusion. Two reviewers also independently extracted data and appraised study quality using the criteria outlined by Harris et al.⁽⁴⁾. Any disagreements or discrepancies were resolved by discussion and consensus. The knowledge synthesis was performed by KY, LZ, and KM and was supervised by the IWG. Following critical appraisal of individual studies, summary tables with ratings of the quality of the evidence using NACI's methodological hierarchy (Table 4 and 5) were prepared, and proposed recommendations for vaccine use developed. The IWG Chair and the Public Health Agency of Canada (PHAC) technical advisor presented the evidence and proposed recommendations to NACI on June 7th, 2018. Following thorough review of the evidence and consultation at the NACI meetings of June 6th–7th, 2018, NACI voted on specific recommendations. The description of relevant considerations, rationale for specific decisions, and knowledge gaps are described in the following sections.

III. VACCINE

III.1 Afluria® Tetra influenza vaccine preparation authorized for use in Canada

Afluria® Tetra is a split virus QIV. It is authorized for intramuscular injection and is available as a single-dose pre-filled syringe without a needle, and as a 5mL multi-dose vial. For more information on Afluria® Tetra, refer to the product monograph⁽⁵⁾.

Table 1. Characteristics of Afluria® Tetra influenza vaccine

Route of Administration	Dosage	Non-medicinal Ingredients
Intramuscular	Each 0.5 mL dose contains 15 μ g of haemagglutinin (HA) of each influenza virus strain	Calcium chloride, dibasic sodium phosphate (anhydrous), monobasic potassium phosphate, monobasic sodium phosphate, potassium chloride, sodium chloride, thimerosal (multi-dose vial only) and water for injection. Each dose may also contain sodium taurodeoxycholate (TDOC), ovalbumin (egg proteins) and trace amounts of betapropiolactone, neomycin sulfate, polymyxin B sulfate and sucrose.

III.2 Vaccine Efficacy and Effectiveness

No studies on the efficacy or effectiveness of Afluria® Tetra or Afluria® (1.5% TDOC formulation) were identified in this review.

III.3 Immunogenicity

Regulators in Canada, the United States (US), and Europe accept non-inferiority immunogenicity trials that compare the haemagglutination inhibition (HI) antibody response of the new vaccine to that of an existing licensed vaccine, or placebo-controlled immunogenicity trials that assess the HI antibody response to the new vaccine. Non-inferiority and placebo-controlled immunogenicity trials are often considered sufficient by regulatory authorities when there are bridging data to correlate immunogenicity outcomes to clinical protection, or when the new vaccines are very similar to vaccines already authorized. Serological assessments based on the geometric mean titres (GMT) of HI antibody that are used by regulators are: GMT ratio, seroprotection rate, and seroconversion rate. The US Food and Drug Administration (FDA) has published definitions for these serological assessments and criteria for immunogenicity data necessary for influenza vaccine licensure⁽⁶⁾. These definitions and currently used criteria are shown in Table 2. Correlates of protection that are not based on HI antibody titres have not been well established.

III.3.1 Immunogenicity in adults

Two studies were identified that assessed the immunogenicity of Afluria® Tetra or Afluria® (1.5% TDOC formulation) in adults^(7,8). Both studies looked at the seroprotection rate and seroconversion rate of haemagglutinin (HA) at 21 days post-vaccination. Only one of the studies assessed GMT ratio. The comparator vaccines for these two studies included TIVs manufactured by Seqirus containing an influenza B/Victoria or an influenza B/Yamagata lineage strain⁽⁷⁾ or no comparator⁽⁸⁾. Additional details on the immunogenicity findings in adults can be found in Table 6.

Afluria® Tetra was non-inferior to the comparator TIVs based on GMT ratios and differences in seroconversion rate for adults 18–64 years of age and ≥65 years of age at 21 days post-vaccination^(7,8). Afluria® Tetra also exceeded the thresholds for seroprotection rate for both of these age groups for all strains except for a B/Yamagata lineage strain in adults ≥65 years of age^(7,8).

III.3.2 Immunogenicity in children

Only one study that assessed the immunogenicity of Afluria® Tetra in children⁽⁹⁾ was found. This study compared the immunogenicity of Afluria® Tetra to that of a comparator QIV (Fluarix® Quadrivalent, GlaxoSmithKline, not authorized for use in Canada). The study compared the GMT ratio, seroprotection rate, and seroconversion rate in the control and intervention groups at 28 days post-vaccination. Additional details on the immunogenicity findings in children are shown in Table 6.

Afluria® Tetra demonstrated non-inferiority to Fluarix® Quadrivalent in children 5–17 years of age, based on GMT ratios and differences in seroconversion rates for all influenza strains⁽⁹⁾. Differences in seroconversion rates were not calculated for the subgroups of children 5–8 years of age and 9–17 years of age; however, seroconversion rates appeared similar between the two groups, as they had widely overlapping confidence intervals (CIs). The vaccine also met the threshold for seroprotection for all strains except for a B/Yamagata lineage strain in the subgroup of children 5–8 years of age⁽⁹⁾.

III.4 Adverse Events

III.4.1 Adverse events in adults

This review found two studies, one peer-reviewed and one not peer-reviewed, that assessed the safety of Afluria® Tetra or Afluria® (1.5% TDOC formulation) in adults^(7,8). The peer-reviewed study made direct comparisons between Afluria® Tetra and TIVs manufactured by Seqirus containing an influenza B/Victoria or an influenza B/Yamagata lineage strain⁽⁷⁾. The study that was not peer-reviewed only reported safety for Enzira®, which is the trade name for Afluria® in the United Kingdom, and did not have a comparator⁽⁸⁾. Further details on the safety evidence for Afluria® Tetra in adults are shown in Table 7.

Among adults who received Afluria® Tetra or Afluria® (1.5% TDOC formulation), 37.4–52.5% experienced solicited local adverse events (AEs), 19.2–28.9% experienced solicited systemic AEs, and 20.5%–44.2% experienced unsolicited AEs^(7,8). The most common AE was pain and specifically pain at the injection site. Overall, there was no difference in the proportion of people who experienced local or systematic AEs between groups that received Afluria® Tetra and groups that received comparable TIVs⁽⁷⁾. The only significant difference reported between the two groups was that participants who received Afluria® Tetra were more likely to experience a headache compared to participants that received a TIV containing a B/Yamagata lineage⁽⁷⁾.

The proportion of participants that received Afluria® Tetra or Afluria® and experienced any serious or severe adverse event (SAE) was 0–2.3% and the proportion that died during the course of the study was 0–0.3%^(7,8). Participants that received TIVs experienced similar proportions of SAEs^(7,8). The investigator of the Treanor et al. study considered four SAEs (one asthma event, one acute pancreatitis event, one hypoxia event, and one pneumonia event) and one death (pneumonia in adult ≥65) as related to Afluria® Tetra⁽⁷⁾. These four SAEs and the one death were not considered vaccine-related by the study sponsor or by the Canadian regulator.

III.4.2 Adverse events in children

Two studies were identified that assessed the safety of Afluria® Tetra or Afluria® (1.5% TDOC formulation) in children^(9,10). One peer-reviewed study compared the safety of Afluria® Tetra to Fluarix® Quadrivalent (GlaxoSmithKline, not authorized for use in Canada)⁽⁹⁾, and one study, not peer-reviewed, compared the safety of Afluria® (1.5% TDOC formulation) to Fluzone® Quadrivalent (Sanofi Pasteur)⁽¹⁰⁾. These studies assessed safety in children 5–17 years of age. No safety data were identified for children <5 years of age. Additional details on the safety evidence for Afluria® Tetra in children are shown in Table 7.

Of children 5–8 years of age that received Afluria® Tetra or Afluria®, 57.2–70.2% experienced local AEs, 27.6–40.8% experienced systemic AEs, and 14.0% experienced unsolicited AEs^(9,10). A comparatively smaller proportion of children 9–17 years of age experienced AEs, with 54.9% having experienced local AEs and 34.1% having experienced systemic AEs⁽⁹⁾. The most common local AE experienced by children aged 5–8^(9,10) and 9–17⁽⁹⁾ was mild pain, and the most common systemic AE experienced by children aged 5–8^(9,10) and 9–17⁽⁹⁾ was headache. Overall, there was no difference in the proportion of children that experienced local or systemic AEs between groups that received Afluria® Tetra or Afluria® and groups that received a comparator QIV. The only notable differences were that the proportion of children with moderate solicited systemic AEs and the proportion that experienced swelling appeared lower in one study for children that received Afluria® compared to a QIV⁽¹⁰⁾, and the proportion of children that

experienced myalgia was significantly higher in one study for children who received Afluria® Tetra compared to children who received Fluarix® Quadrivalent⁽⁹⁾.

The overall proportion of children that experienced SAEs was low, with 0.47% of children 5–17 years of age⁽⁹⁾ and 0.003% of children 5–8 years of age⁽¹⁰⁾ experiencing any SAE. Participants that received a comparator QIV had comparable proportions of SAEs.

Fever and febrile seizures

During Western Australia's 2010 Southern Hemisphere influenza season surveillance, a safety signal was detected for the use of Afluria® (trivalent formulation) in children⁽³⁾. The trivalent formulation of Afluria® was found to be associated with an increased rate of fever and febrile seizures in children <5 years of age⁽¹¹⁾. An investigation by the manufacturer into this event revealed that the manufacturing process for Afluria® resulted in degraded ribonucleic acid (RNA) fragments being delivered by residual lipids, which increased the release of proinflammatory cytokines⁽¹²⁾. Further studies demonstrated that the release of proinflammatory cytokines was attenuated by an increased concentration of the splitting agent TDOC; therefore, the manufacturing process for Afluria® was modified to use 1.5% weight/volume TDOC as opposed to 0.9% for A(H1N1), 1.5% for A(H3N2), and 0.5% for B, which were the concentrations used previously⁽¹²⁾. This modified manufacturing process is used for Afluria® Tetra.

In the two studies identified in this review, both reported on the proportion of participants who experienced fever or febrile seizures. The evidence shows no statistically significant difference in the proportion of children that experienced any, mild, moderate, or severe fever^(9, 10) between groups that received Afluria® Tetra or Afluria® (1.5% TDOC formulation) and groups that received a comparator QIV. There also appeared to be no difference in the proportion that experienced any vaccine-related fever event⁽¹⁰⁾; however, statistical significance was not reported for this outcome. No seizure or febrile seizure events were reported in either of the studies for any of the vaccines investigated^(9, 10).

IV. RECOMMENDATIONS

1. NACI recommends that Afluria® Tetra may be considered among the QIVs offered to adults and children ≥5 years of age (Discretionary NACI Recommendation)

- NACI concludes that there is fair evidence to recommend vaccination of adults and children ≥5 years of age (Grade B Evidence)

There is good evidence that Afluria® Tetra is safe and has non-inferior immunogenicity to comparable vaccines based on direct evidence in adults and children ≥5 years of age. The evidence is considered Grade B as there is no direct evidence on the efficacy or effectiveness of Afluria® Tetra. There is no evidence on the efficacy, effectiveness, immunogenicity, or safety for the use of Afluria® Tetra in children <5 years of age, and Afluria® Tetra is not authorized for use in this age group in Canada.

TABLES

Table 2. Serological Assay Definitions and Thresholds for Protection Specified by the United States Food and Drug Administration⁽⁶⁾

Serological assay	Definition	Threshold
<i>GMT ratio</i>	Ratio of GMT post-vaccination of licensed vaccine to GMT post-vaccination of new vaccine	Non-inferiority: The upper bound of the two-sided 95% CI on the ratio of the GMTs should not exceed 1.5.
<i>Seroprotection</i>	Proportion of subjects achieving an HI titre of $\geq 1:40$ post-vaccination	Placebo-controlled: Lower limit of the two-sided 95% CI for the percent of subjects achieving seroprotection should meet or exceed 70% (for adults <65 and children) or 60% (for adults ≥ 65)
<i>Seroconversion</i>	Proportion of subjects achieving an increase from $\leq 1:10$ HI titre pre-vaccination to $\geq 1:40$ post-vaccination or achieving at least four-fold rise in HI titres	Non-inferiority: Upper limit of the two-sided 95% CI on the difference between the seroconversion rates (rate of licensed vaccine – rate of new vaccine) should not exceed 10 percentage points. Placebo-controlled: Lower limit of the two-sided 95% CI for the percent of subjects achieving seroprotection should meet or exceed 40% (for adults <65 and children) or 30% (for adults ≥ 65)

Abbreviations: CI: confidence interval, GMT: geometric mean titre, HI: haemagglutination inhibition

Table 3. NACI Recommendations: Strength of Recommendation and Grade of Evidence

STRENGTH OF NACI RECOMMENDATION	GRADE OF EVIDENCE
<p>Based on factors not isolated to strength of evidence (e.g. public health need)</p> <p>Strong "should/should not be offered"</p> <ul style="list-style-type: none"> ➤ Known/Anticipated advantages outweigh known/anticipated disadvantages ("should"), OR Known/Anticipated disadvantages outweigh known/anticipated advantages ("should not") ➤ Implication: A strong recommendation applies to most populations/individuals and should be followed unless a clear and compelling rationale for an alternative approach is present 	<p>Based on assessment of the body of evidence</p> <p>A - <i>good evidence</i> to recommend</p> <p>B – <i>fair evidence</i> to recommend</p> <p>C – <i>conflicting evidence</i>, however other factors may influence decision-making</p> <p>D – <i>fair evidence</i> to recommend against</p> <p>E – <i>good evidence</i> to recommend against</p> <p>I – <i>insufficient evidence</i> (in quality or quantity), however other factors may influence decision-making</p>
<p>Discretionary "may be considered"</p> <ul style="list-style-type: none"> ➤ Known/Anticipated advantages closely balanced with known/anticipated disadvantages, OR uncertainty in the evidence of advantages and disadvantages exists ➤ Implication: A discretionary recommendation may be considered for some populations/individuals in some circumstances. Alternative approaches may be reasonable 	<p>A - <i>good evidence</i> to recommend</p> <p>B – <i>fair evidence</i> to recommend</p> <p>C – <i>conflicting evidence</i>, however other factors may influence decision-making</p> <p>D – <i>fair evidence</i> to recommend against</p> <p>E – <i>good evidence</i> to recommend against</p> <p>I – <i>insufficient evidence</i> (in quality or quantity), however other factors may influence decision-making</p>

Table 4. Ranking Individual Studies: Levels of Evidence Based on Research Design

Level	Description
I	Evidence from randomized controlled trial(s).
II-1	Evidence from controlled trial(s) without randomization.
II-2	Evidence from cohort or case-control analytic studies, preferably from more than one centre or research group using clinical outcome measures of vaccine efficacy.
II-3	Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
III	Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.

Table 5. Ranking Individual Studies: Quality (internal validity) Rating of Evidence

Quality Rating	Description
Good	A study (including meta-analyses or systematic reviews) that meets all design- specific criteria* well.
Fair	A study (including meta-analyses or systematic reviews) that does not meet (or it is not clear that it meets) at least one design-specific criterion* but has no known "fatal flaw".
Poor	A study (including meta-analyses or systematic reviews) that has at least one design-specific* "fatal flaw", or an accumulation of lesser flaws to the extent that the results of the study are not deemed able to inform recommendations.

*General design specific criteria are outlined in Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D. Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med. 2001;20(3):21-35.⁽⁴⁾

Table 6. Summary of Evidence on the Immunogenicity of Afluria® Tetra

STUDY DETAILS					SUMMARY																											
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality																										
Airey J, Albano FR, Sawlwin DC, Jones AG, Fromica N, Matassa V, Leong J. <i>Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.</i> Vaccine, 2017;35(20) ⁽⁹⁾	Afluria® Tetra	RCT US Multicentre 2015–2016 influenza season Funded by Seqirus	Healthy children 5–17 years of age 47.9% female Group 1: 1709 children vaccinated with Afluria® Tetra Group 2: 569 children vaccinated with Fluarix® Quadrivalent	GMT ratio 28 days post-vaccination (Group 2/Group 1): <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>5–17</td> <td>A(H1N1)</td> <td>1.01 (0.93, 1.09)</td> </tr> <tr> <td>5–17</td> <td>A(H3N2)</td> <td>1.05 (0.96, 1.15)</td> </tr> <tr> <td>5–17</td> <td>B/Yam</td> <td>0.89 (0.81, 0.98)</td> </tr> <tr> <td>5–17</td> <td>B/Vic</td> <td>0.92 (0.83, 1.02)</td> </tr> </tbody> </table>	Age	Strain	Estimate (95% CI)	5–17	A(H1N1)	1.01 (0.93, 1.09)	5–17	A(H3N2)	1.05 (0.96, 1.15)	5–17	B/Yam	0.89 (0.81, 0.98)	5–17	B/Vic	0.92 (0.83, 1.02)	I	Good											
				Age	Strain	Estimate (95% CI)																										
				5–17	A(H1N1)	1.01 (0.93, 1.09)																										
				5–17	A(H3N2)	1.05 (0.96, 1.15)																										
				5–17	B/Yam	0.89 (0.81, 0.98)																										
				5–17	B/Vic	0.92 (0.83, 1.02)																										
				Difference in seroconversion rate 28 days post-vaccination (Group 2 – Group 1): <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>5–17</td> <td>A(H1N1)</td> <td>-3.1 (-8.0, 1.8)</td> </tr> <tr> <td>5–17</td> <td>A(H3N2)</td> <td>0.4 (-4.5, 5.3)</td> </tr> <tr> <td>5–17</td> <td>B/Yam¹</td> <td>-3.4 (-8.3, 1.5)</td> </tr> <tr> <td>5–17</td> <td>B/Vic⁺</td> <td>-2.0 (-6.9, 2.9)</td> </tr> </tbody> </table>	Age	Strain	Estimate (95% CI)	5–17	A(H1N1)	-3.1 (-8.0, 1.8)	5–17	A(H3N2)	0.4 (-4.5, 5.3)	5–17	B/Yam ¹	-3.4 (-8.3, 1.5)	5–17	B/Vic ⁺	-2.0 (-6.9, 2.9)													
				Age	Strain	Estimate (95% CI)																										
				5–17	A(H1N1)	-3.1 (-8.0, 1.8)																										
				5–17	A(H3N2)	0.4 (-4.5, 5.3)																										
				5–17	B/Yam ¹	-3.4 (-8.3, 1.5)																										
				5–17	B/Vic ⁺	-2.0 (-6.9, 2.9)																										
				Seroconversion rate 28 days post-vaccination: <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Group 1 (95% CI)</th> <th>Group 2 (95% CI)</th> </tr> </thead> <tbody> <tr> <td>5–17</td> <td>A(H1N1)</td> <td>66.4 (64.0, 68.7)</td> <td>63.3 (59.0, 67.4)</td> </tr> <tr> <td>5–17</td> <td>A(H3N2)</td> <td>82.9 (81.0, 84.7)</td> <td>83.3 (79.9, 86.4)</td> </tr> <tr> <td>5–17</td> <td>B/Yam</td> <td>58.5 (56.0, 60.9)</td> <td>55.1 (50.8, 59.4)</td> </tr> <tr> <td>5–17</td> <td>B/Vic</td> <td>72.1 (69.8, 74.3)</td> <td>70.1 (66.0, 74.0)</td> </tr> <tr> <td>5–8</td> <td>A(H1N1)</td> <td>67.9 (64.6, 71.2)</td> <td>67.2 (61.1, 72.8)</td> </tr> <tr> <td>5–8</td> <td>A(H3N2)</td> <td>83.3 (80.5, 85.8)</td> <td>82.4 (77.3, 86.8)</td> </tr> <tr> <td>5–8</td> <td>B/Yam</td> <td>55.7 (52.2, 59.2)</td> <td>55.3 (49.1, 61.5)</td> </tr> </tbody> </table>	Age	Strain	Group 1 (95% CI)	Group 2 (95% CI)	5–17	A(H1N1)	66.4 (64.0, 68.7)	63.3 (59.0, 67.4)	5–17	A(H3N2)	82.9 (81.0, 84.7)	83.3 (79.9, 86.4)	5–17	B/Yam	58.5 (56.0, 60.9)			55.1 (50.8, 59.4)	5–17	B/Vic	72.1 (69.8, 74.3)	70.1 (66.0, 74.0)	5–8	A(H1N1)	67.9 (64.6, 71.2)	67.2 (61.1, 72.8)	5–8	A(H3N2)
Age	Strain	Group 1 (95% CI)	Group 2 (95% CI)																													
5–17	A(H1N1)	66.4 (64.0, 68.7)	63.3 (59.0, 67.4)																													
5–17	A(H3N2)	82.9 (81.0, 84.7)	83.3 (79.9, 86.4)																													
5–17	B/Yam	58.5 (56.0, 60.9)	55.1 (50.8, 59.4)																													
5–17	B/Vic	72.1 (69.8, 74.3)	70.1 (66.0, 74.0)																													
5–8	A(H1N1)	67.9 (64.6, 71.2)	67.2 (61.1, 72.8)																													
5–8	A(H3N2)	83.3 (80.5, 85.8)	82.4 (77.3, 86.8)																													
5–8	B/Yam	55.7 (52.2, 59.2)	55.3 (49.1, 61.5)																													

STUDY DETAILS					SUMMARY																																																												
Study	Vaccine	Study Design	Participants	Summary of Key Findings		Level of Evidence	Quality																																																										
				<table border="1"> <tr> <td>5-8</td> <td>B/Vic</td> <td>73.6 (70.4, 76.6)</td> <td>73.7 (67.9, 78.9)</td> </tr> <tr> <td>9-17</td> <td>A(H1N1)</td> <td>64.8 (61.4, 68.1)</td> <td>59.4 (53.2, 65.4)</td> </tr> <tr> <td>9-17</td> <td>A(H3N2)</td> <td>82.6 (79.8, 85.1)</td> <td>84.2 (79.3, 88.4)</td> </tr> <tr> <td>9-17</td> <td>B/Yam</td> <td>61.2 (57.8, 64.6)</td> <td>54.9 (48.7, 61.0)</td> </tr> <tr> <td>9-17</td> <td>B/Vic</td> <td>70.6 (67.3, 73.7)</td> <td>66.5 (60.5, 72.2)</td> </tr> </table> <p>Seroprotection rate 28 days post-vaccination (Group 1):</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr><td>5-17</td><td>A(H1N1)</td><td>99.7 (99.3, 99.9)</td></tr> <tr><td>5-17</td><td>A(H3N2)</td><td>99.4 (98.9, 99.7)</td></tr> <tr><td>5-17</td><td>B/Yam</td><td>75.0 (72.8, 77.1)</td></tr> <tr><td>5-17</td><td>B/Vic</td><td>90.3 (88.7, 91.7)</td></tr> <tr><td>5-8</td><td>A(H1N1)</td><td>99.6 (98.9, 99.9)</td></tr> <tr><td>5-8</td><td>A(H3N2)</td><td>99.2 (98.4, 99.7)</td></tr> <tr><td>5-8</td><td>B/Yam</td><td>69.2 (65.8, 72.4)</td></tr> <tr><td>5-8</td><td>B/Vic</td><td>88.4 (86.0, 90.6)</td></tr> <tr><td>9-17</td><td>A(H1N1)</td><td>99.8 (99.1, 100.0)</td></tr> <tr><td>9-17</td><td>A(H3N2)</td><td>99.6 (98.9, 99.9)</td></tr> <tr><td>9-17</td><td>B/Yam</td><td>80.6 (77.7, 83.3)</td></tr> <tr><td>9-17</td><td>B/Vic</td><td>92.1 (90.0, 93.9)</td></tr> </tbody> </table> <p>There were no potentially important differences in GMFR between the two groups.</p>	5-8	B/Vic	73.6 (70.4, 76.6)	73.7 (67.9, 78.9)	9-17	A(H1N1)	64.8 (61.4, 68.1)	59.4 (53.2, 65.4)	9-17	A(H3N2)	82.6 (79.8, 85.1)	84.2 (79.3, 88.4)	9-17	B/Yam	61.2 (57.8, 64.6)	54.9 (48.7, 61.0)	9-17	B/Vic	70.6 (67.3, 73.7)	66.5 (60.5, 72.2)	Age	Strain	Estimate (95% CI)	5-17	A(H1N1)	99.7 (99.3, 99.9)	5-17	A(H3N2)	99.4 (98.9, 99.7)	5-17	B/Yam	75.0 (72.8, 77.1)	5-17	B/Vic	90.3 (88.7, 91.7)	5-8	A(H1N1)	99.6 (98.9, 99.9)	5-8	A(H3N2)	99.2 (98.4, 99.7)	5-8	B/Yam	69.2 (65.8, 72.4)	5-8	B/Vic	88.4 (86.0, 90.6)	9-17	A(H1N1)	99.8 (99.1, 100.0)	9-17	A(H3N2)	99.6 (98.9, 99.9)	9-17	B/Yam	80.6 (77.7, 83.3)	9-17	B/Vic	92.1 (90.0, 93.9)		
5-8	B/Vic	73.6 (70.4, 76.6)	73.7 (67.9, 78.9)																																																														
9-17	A(H1N1)	64.8 (61.4, 68.1)	59.4 (53.2, 65.4)																																																														
9-17	A(H3N2)	82.6 (79.8, 85.1)	84.2 (79.3, 88.4)																																																														
9-17	B/Yam	61.2 (57.8, 64.6)	54.9 (48.7, 61.0)																																																														
9-17	B/Vic	70.6 (67.3, 73.7)	66.5 (60.5, 72.2)																																																														
Age	Strain	Estimate (95% CI)																																																															
5-17	A(H1N1)	99.7 (99.3, 99.9)																																																															
5-17	A(H3N2)	99.4 (98.9, 99.7)																																																															
5-17	B/Yam	75.0 (72.8, 77.1)																																																															
5-17	B/Vic	90.3 (88.7, 91.7)																																																															
5-8	A(H1N1)	99.6 (98.9, 99.9)																																																															
5-8	A(H3N2)	99.2 (98.4, 99.7)																																																															
5-8	B/Yam	69.2 (65.8, 72.4)																																																															
5-8	B/Vic	88.4 (86.0, 90.6)																																																															
9-17	A(H1N1)	99.8 (99.1, 100.0)																																																															
9-17	A(H3N2)	99.6 (98.9, 99.9)																																																															
9-17	B/Yam	80.6 (77.7, 83.3)																																																															
9-17	B/Vic	92.1 (90.0, 93.9)																																																															
Treanor JT, Albano FR, Sawlwin DC, Jones AG, Airey J, Formica N, Matassa V, Leong J. <i>Immunogenicity and safety of a quadrivalent</i>	Afluria® Tetra	RCT US Multicentre 2014-2015	Healthy adults ≥18 years of age 57.2% female Group 1:	<p>GMT ratio 21 days post-vaccination (Group 2/Group 1):</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr><td>≥18</td><td>A(H1N1)</td><td>0.93 (0.88, 0.99)</td></tr> <tr><td>≥18</td><td>A(H3N2)</td><td>0.93 (0.88, 0.98)</td></tr> <tr><td>≥18</td><td>B/Yam[†]</td><td>0.87 (0.82, 0.93)</td></tr> </tbody> </table>	Age	Strain	Estimate (95% CI)	≥18	A(H1N1)	0.93 (0.88, 0.99)	≥18	A(H3N2)	0.93 (0.88, 0.98)	≥18	B/Yam [†]	0.87 (0.82, 0.93)	I	Good																																															
Age	Strain	Estimate (95% CI)																																																															
≥18	A(H1N1)	0.93 (0.88, 0.99)																																																															
≥18	A(H3N2)	0.93 (0.88, 0.98)																																																															
≥18	B/Yam [†]	0.87 (0.82, 0.93)																																																															

STUDY DETAILS					SUMMARY			
Study	Vaccine	Study Design	Participants	Summary of Key Findings			Level of Evidence	Quality
<i>inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study, Vaccine, 2017;35(15)</i> ⁽⁷⁾		influenza season Funded by Seqirus	1741 adults vaccinated with Afluria® Tetra Group 2: 1743 adults vaccinated with a Seqirus-manufactured TIV containing a B/Yamagata strain (n=871) or a B/Victoria strain (n=872)	≥18	B/Vic [‡]	0.95 (0.88, 1.03)		
				18–64	A(H1N1)	0.93 (0.85, 1.02)		
				18–64	A(H3N2)	0.91 (0.83, 0.99)		
				18–64	B/Yam [†]	0.86 (0.76, 0.97)		
				18–64	B/Vic [‡]	0.86 (0.76, 0.98)		
				≥65	A(H1N1)	0.95 (0.88, 1.02)		
				≥65	A(H3N2)	0.95 (0.89, 1.02)		
				≥65	B/Yam [†]	0.90 (0.84, 0.97)		
				≥65	B/Vic [‡]	1.03 (0.94, 1.14)		
				[†] Only participants that received the TIV containing a B/Yamagata strain [‡] Only participants that received the TIV containing a B/Victoria strain				
				Difference in seroconversion rate 21 days post-vaccination (Group 2 - Group 1):				
				Age	Strain	Estimate (95% CI)		
				≥18	A(H1N1)	-1.1 (-4.5, 2.3)		
				≥18	A(H3N2)	-1.7 (-5.0, 1.7)		
				≥18	B/Yam [†]	-3.2 (-7.4, 0.9)		
				≥18	B/Vic [‡]	-1.6 (-5.8, 2.5)		
				18–64	A(H1N1)	-2.1 (-6.9, 2.7)		
				18–64	A(H3N2)	-4.6 (-9.4, 0.2)		
				18–64	B/Yam [†]	-4.5 (-10.3, 1.4)		
				18–64	B/Vic [‡]	-4.6 (-10.5, 1.2)		
≥65	A(H1N1)	-0.2 (-5.0, 4.5)						
≥65	A(H3N2)	1.1 (-3.7, 5.8)						
≥65	B/Yam [†]	-2.2 (-8.0, 3.6)						
≥65	B/Vic [‡]	1.2 (-4.6, 7.0)						
[†] Only participants that received the TIV containing a B/Yamagata strain [‡] Only participants that received the TIV containing a B/Victoria strain								
Seroprotection rate 21 days post-vaccination (Group 1):								

STUDY DETAILS					SUMMARY																												
Study	Vaccine	Study Design	Participants	Summary of Key Findings			Level of Evidence	Quality																									
				<table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>18–64</td> <td>A(H1N1)</td> <td>99.0 (98.1, 99.6)</td> </tr> <tr> <td>18–64</td> <td>A(H3N2)</td> <td>99.0 (98.1, 99.6)</td> </tr> <tr> <td>18–64</td> <td>B/Yam[†]</td> <td>84.3 (81.7, 86.7)</td> </tr> <tr> <td>18–64</td> <td>B/Vic[‡]</td> <td>86.7 (84.2, 88.9)</td> </tr> <tr> <td>≥65</td> <td>A(H1N1)</td> <td>94.6 (92.9, 96.0)</td> </tr> <tr> <td>≥65</td> <td>A(H3N2)</td> <td>99.8 (99.2, 100.0)</td> </tr> <tr> <td>≥65</td> <td>B/Yam[†]</td> <td>57.5 (54.1, 60.8)</td> </tr> <tr> <td>≥65</td> <td>B/Vic[‡]</td> <td>68.3 (65.1, 71.4)</td> </tr> </tbody> </table> <p>[†] Only participants that received the TIV containing a B/Yamagata strain [‡] Only participants that received the TIV containing a B/Victoria strain</p> <p>GMFR was also reported and showed no concerns; however, the difference in GMFR was not reported.</p>	Age	Strain	Estimate (95% CI)	18–64	A(H1N1)	99.0 (98.1, 99.6)	18–64	A(H3N2)	99.0 (98.1, 99.6)	18–64	B/Yam [†]	84.3 (81.7, 86.7)	18–64	B/Vic [‡]	86.7 (84.2, 88.9)	≥65	A(H1N1)	94.6 (92.9, 96.0)	≥65	A(H3N2)	99.8 (99.2, 100.0)	≥65	B/Yam [†]	57.5 (54.1, 60.8)	≥65	B/Vic [‡]	68.3 (65.1, 71.4)		
Age	Strain	Estimate (95% CI)																															
18–64	A(H1N1)	99.0 (98.1, 99.6)																															
18–64	A(H3N2)	99.0 (98.1, 99.6)																															
18–64	B/Yam [†]	84.3 (81.7, 86.7)																															
18–64	B/Vic [‡]	86.7 (84.2, 88.9)																															
≥65	A(H1N1)	94.6 (92.9, 96.0)																															
≥65	A(H3N2)	99.8 (99.2, 100.0)																															
≥65	B/Yam [†]	57.5 (54.1, 60.8)																															
≥65	B/Vic [‡]	68.3 (65.1, 71.4)																															
ClinicalTrials.gov <i>A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira Vaccine in Healthy Volunteers.</i> NCT01863433. ⁽⁸⁾	Enzira [®] (Afluria [®] in other countries)	RCT England Single-centre 2013–2014 influenza season Sponsored by Seqirus	Healthy adults 18–59 years of age 52.5% female Group 1: 120 adults vaccinated with Enzira [®] (Afluria [®] in other jurisdictions) No control arm	Seroconversion rate 21 days post-vaccination (Group 1): <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>18–59</td> <td>A(H1N1)</td> <td>79 (70.6, 85.9)</td> </tr> <tr> <td>18–59</td> <td>A(H3N2)</td> <td>79 (70.6, 85.9)</td> </tr> <tr> <td>18–59</td> <td>B/Yam</td> <td>64.7 (55.4, 73.2)</td> </tr> </tbody> </table> Seroprotection rate 21 days post-vaccination (Group 1): <table border="1"> <thead> <tr> <th>Age</th> <th>Strain</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>18–59</td> <td>A(H1N1)</td> <td>97.5 (92.8, 99.5)</td> </tr> <tr> <td>18–59</td> <td>A(H3N2)</td> <td>99.2 (95.4, 100.0)</td> </tr> <tr> <td>18–59</td> <td>B/Yam</td> <td>95.0 (89.3, 98.1)</td> </tr> </tbody> </table> <p>There were no potentially important differences in GMFR between the two groups.</p>	Age	Strain	Estimate (95% CI)	18–59	A(H1N1)	79 (70.6, 85.9)	18–59	A(H3N2)	79 (70.6, 85.9)	18–59	B/Yam	64.7 (55.4, 73.2)	Age	Strain	Estimate (95% CI)	18–59	A(H1N1)	97.5 (92.8, 99.5)	18–59	A(H3N2)	99.2 (95.4, 100.0)	18–59	B/Yam	95.0 (89.3, 98.1)	I	n/a Phase IV study that has not been peer-reviewed and did not contain a control group.			
Age	Strain	Estimate (95% CI)																															
18–59	A(H1N1)	79 (70.6, 85.9)																															
18–59	A(H3N2)	79 (70.6, 85.9)																															
18–59	B/Yam	64.7 (55.4, 73.2)																															
Age	Strain	Estimate (95% CI)																															
18–59	A(H1N1)	97.5 (92.8, 99.5)																															
18–59	A(H3N2)	99.2 (95.4, 100.0)																															
18–59	B/Yam	95.0 (89.3, 98.1)																															

Abbreviations: CI: confidence interval; GMFR: geometric mean fold rise; GMT: geometric mean titre; n/a: not applicable; RCT: randomized controlled trial; TIV: trivalent inactivated influenza vaccine; US: United States

Table 7. Summary of Evidence on the Safety of Afluria® Tetra

STUDY DETAILS					SUMMARY																					
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality																				
Airey J, Albano FR, Sawlwin DC, Jones AG, Fromica N, Matassa V, Leong J. <i>Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.</i> Vaccine, 2017;35(20) ⁽⁹⁾	Afluria® Tetra	RCT US Multicentre 2015–2016 influenza season Funded by Seqirus	Healthy children 5–17 years of age 47.9% female Group 1: 1709 children vaccinated with Afluria® Tetra Group 2: 569 children vaccinated with Fluarix® Quadrivalent	Proportion of children 5–17 years of age experiencing AE and SAE:	I	Good																				
				<table border="1"> <thead> <tr> <th>Age</th> <th>Outcome</th> <th>Group 1</th> <th>Group 2</th> </tr> </thead> <tbody> <tr> <td>5–17</td> <td>AE, solicited local</td> <td>56.1%</td> <td>52.1%</td> </tr> <tr> <td>5–17</td> <td>AE, solicited systemic</td> <td>30.8%</td> <td>27.5%</td> </tr> <tr> <td>5–17</td> <td>AE, unsolicited</td> <td>15.9%</td> <td>12.5%</td> </tr> <tr> <td>5–17</td> <td>SAE, any</td> <td>0.47%</td> <td>0.36%</td> </tr> </tbody> </table>			Age	Outcome	Group 1	Group 2	5–17	AE, solicited local	56.1%	52.1%	5–17	AE, solicited systemic	30.8%	27.5%	5–17	AE, unsolicited	15.9%	12.5%	5–17	SAE, any	0.47%	0.36%
				Age			Outcome	Group 1	Group 2																	
				5–17			AE, solicited local	56.1%	52.1%																	
				5–17			AE, solicited systemic	30.8%	27.5%																	
				5–17			AE, unsolicited	15.9%	12.5%																	
				5–17			SAE, any	0.47%	0.36%																	
				RR of AE (Group 1/Group 2):																						
				<table border="1"> <thead> <tr> <th>Age</th> <th>Outcome</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>5–8</td> <td>AE, solicited local</td> <td>1.06 (0.93, 1.20)</td> </tr> <tr> <td>5–8</td> <td>AE, solicited systemic</td> <td>1.05 (0.84, 1.31)</td> </tr> <tr> <td>9–17</td> <td>AE, solicited local</td> <td>1.09 (0.95, 1.25)</td> </tr> <tr> <td>9–17</td> <td>AE, solicited systemic</td> <td>1.19 (0.96, 1.47)</td> </tr> </tbody> </table>			Age	Outcome	Estimate (95% CI)	5–8	AE, solicited local	1.06 (0.93, 1.20)	5–8	AE, solicited systemic	1.05 (0.84, 1.31)	9–17	AE, solicited local	1.09 (0.95, 1.25)	9–17	AE, solicited systemic	1.19 (0.96, 1.47)					
				Age			Outcome	Estimate (95% CI)																		
5–8	AE, solicited local	1.06 (0.93, 1.20)																								
5–8	AE, solicited systemic	1.05 (0.84, 1.31)																								
9–17	AE, solicited local	1.09 (0.95, 1.25)																								
9–17	AE, solicited systemic	1.19 (0.96, 1.47)																								
RR of fever (Group 1/Group 2):																										
<table border="1"> <thead> <tr> <th>Age</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>5–8</td> <td>1.22 (0.62, 2.43)</td> </tr> <tr> <td>9–17</td> <td>2.80 (0.62, 12.04)</td> </tr> </tbody> </table>	Age	Estimate (95% CI)	5–8	1.22 (0.62, 2.43)	9–17	2.80 (0.62, 12.04)																				
Age	Estimate (95% CI)																									
5–8	1.22 (0.62, 2.43)																									
9–17	2.80 (0.62, 12.04)																									
The most common local AE for children 5–17 years of age was injection site pain, and the most common systemic AEs were headache and myalgia. There were no seizures or febrile																										

STUDY DETAILS					SUMMARY																																																		
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality																																																	
				seizures reported in either group. A greater proportion of children in Group 1 experienced myalgia than Group 2.																																																			
Treanor JT, Albano FR, Sawlwin DC, Jones AG, Airey J, Formica N, Matassa V, Leong J. <i>Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study, Vaccine, 2017;35(15)⁽⁷⁾</i>	Afluria® Tetra	RCT US Multicentre 2014–2015 influenza season Funded by Seqirus	Healthy adults ≥18 years of age 57.2% female Group 1: 1741 adults vaccinated with Afluria® Tetra Group 2: 1745 adults vaccinated with a Seqirus-manufactured TIV containing a B/Yamagata strain (n=871) or TIV containing a B/Victoria strain (n=872)	Proportion of adults ≥18 years of age experiencing AE and SAE: <table border="1"> <thead> <tr> <th>Outcome</th> <th>Group 1</th> <th>Group 2 (B/Yam)</th> <th>Group 2 (B/Vic)</th> </tr> </thead> <tbody> <tr> <td>AE, any</td> <td>52.9%</td> <td>53.1%</td> <td>52.5%</td> </tr> <tr> <td>AE, vaccine-related</td> <td>43.8%</td> <td>42.1%</td> <td>42.4%</td> </tr> <tr> <td>AE, unsolicited</td> <td>20.5%</td> <td>22.1%</td> <td>20.4%</td> </tr> <tr> <td>SAE, any</td> <td>2.3%</td> <td>1.6%</td> <td>1.5%</td> </tr> <tr> <td>SAE, vaccine-related</td> <td>0.2%[†]</td> <td>0%</td> <td>0%</td> </tr> <tr> <td>SAE, death</td> <td>0.3%[‡]</td> <td>0%</td> <td>0.1%</td> </tr> </tbody> </table> <p>[†] 1 asthma, 1 acute pancreatitis, 1 hypoxia, and 1 pneumonia [‡] 1 vaccine-related death (pneumonia in adult ≥65)</p> <p>RR of solicited AE (Group 1/Group 2 vaccinated with B/Yamagata TIV only):</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Outcome</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>≥18</td> <td>AE, local</td> <td>1.08 (0.97, 1.21)</td> </tr> <tr> <td>≥18</td> <td>AE, systemic</td> <td>1.02 (0.90, 1.16)</td> </tr> <tr> <td>18–64</td> <td>AE, local</td> <td>1.10 (0.96, 1.24)</td> </tr> <tr> <td>18–64</td> <td>AE, systemic</td> <td>1.05 (0.90, 1.22)</td> </tr> <tr> <td>≥65</td> <td>AE, local</td> <td>1.06 (0.87, 1.28)</td> </tr> <tr> <td>≥65</td> <td>AE, systemic</td> <td>0.97 (0.77, 1.21)</td> </tr> </tbody> </table> <p>RR of solicited AE (Group 1/Group 2 vaccinated with B/Victoria TIV only):</p>	Outcome	Group 1	Group 2 (B/Yam)	Group 2 (B/Vic)	AE, any	52.9%	53.1%	52.5%	AE, vaccine-related	43.8%	42.1%	42.4%	AE, unsolicited	20.5%	22.1%	20.4%	SAE, any	2.3%	1.6%	1.5%	SAE, vaccine-related	0.2% [†]	0%	0%	SAE, death	0.3% [‡]	0%	0.1%	Age	Outcome	Estimate (95% CI)	≥18	AE, local	1.08 (0.97, 1.21)	≥18	AE, systemic	1.02 (0.90, 1.16)	18–64	AE, local	1.10 (0.96, 1.24)	18–64	AE, systemic	1.05 (0.90, 1.22)	≥65	AE, local	1.06 (0.87, 1.28)	≥65	AE, systemic	0.97 (0.77, 1.21)	I	Good
Outcome	Group 1	Group 2 (B/Yam)	Group 2 (B/Vic)																																																				
AE, any	52.9%	53.1%	52.5%																																																				
AE, vaccine-related	43.8%	42.1%	42.4%																																																				
AE, unsolicited	20.5%	22.1%	20.4%																																																				
SAE, any	2.3%	1.6%	1.5%																																																				
SAE, vaccine-related	0.2% [†]	0%	0%																																																				
SAE, death	0.3% [‡]	0%	0.1%																																																				
Age	Outcome	Estimate (95% CI)																																																					
≥18	AE, local	1.08 (0.97, 1.21)																																																					
≥18	AE, systemic	1.02 (0.90, 1.16)																																																					
18–64	AE, local	1.10 (0.96, 1.24)																																																					
18–64	AE, systemic	1.05 (0.90, 1.22)																																																					
≥65	AE, local	1.06 (0.87, 1.28)																																																					
≥65	AE, systemic	0.97 (0.77, 1.21)																																																					

STUDY DETAILS					SUMMARY																															
Study	Vaccine	Study Design	Participants	Summary of Key Findings			Level of Evidence	Quality																												
				<table border="1"> <thead> <tr> <th>Age</th> <th>Outcome</th> <th>Estimate (95% CI)</th> </tr> </thead> <tbody> <tr> <td>≥18</td> <td>AE, local</td> <td>1.02 (0.92, 1.14)</td> </tr> <tr> <td>≥18</td> <td>AE, systemic</td> <td>1.06 (0.93, 1.21)</td> </tr> <tr> <td>18–64</td> <td>AE, local</td> <td>0.94 (0.84, 1.06)</td> </tr> <tr> <td>18–64</td> <td>AE, systemic</td> <td>1.07 (0.92, 1.25)</td> </tr> <tr> <td>≥65</td> <td>AE, local</td> <td>1.22 (0.99, 1.50)</td> </tr> <tr> <td>≥65</td> <td>AE, systemic</td> <td>1.06 (0.83, 1.34)</td> </tr> </tbody> </table> <p>The most common local AE for adults 18–64 and ≥65 years of age was pain, and the most common systemic AEs were headache and myalgia. Participants in Group 1 were more likely to experience a headache compared to participants in Group 2 that received a TIV containing B/Yamagata.</p>	Age	Outcome	Estimate (95% CI)	≥18	AE, local	1.02 (0.92, 1.14)	≥18	AE, systemic	1.06 (0.93, 1.21)	18–64	AE, local	0.94 (0.84, 1.06)	18–64	AE, systemic	1.07 (0.92, 1.25)	≥65	AE, local	1.22 (0.99, 1.50)	≥65	AE, systemic	1.06 (0.83, 1.34)											
Age	Outcome	Estimate (95% CI)																																		
≥18	AE, local	1.02 (0.92, 1.14)																																		
≥18	AE, systemic	1.06 (0.93, 1.21)																																		
18–64	AE, local	0.94 (0.84, 1.06)																																		
18–64	AE, systemic	1.07 (0.92, 1.25)																																		
≥65	AE, local	1.22 (0.99, 1.50)																																		
≥65	AE, systemic	1.06 (0.83, 1.34)																																		
ClinicalTrials.gov <i>A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to <9 Years.</i> NCT02212106. ⁽¹⁰⁾	Afluria®	RCT US Multicentre 2015–2016 influenza season Sponsored by Seqirus	Healthy children 5–8 years of age 48.0% female Group 1: 302 children vaccinated with Afluria® Group 2: 100 children vaccinated with Fluzone® Quadrivalent	Proportion of children 5–8 years of age experiencing AE and SAE: <table border="1"> <thead> <tr> <th>Outcome</th> <th>Group 1</th> <th>Group 2</th> </tr> </thead> <tbody> <tr> <td>AE, solicited local</td> <td>70.2%</td> <td>68.4%</td> </tr> <tr> <td>AE, solicited systemic</td> <td>40.8%</td> <td>44.9%</td> </tr> <tr> <td>AE, unsolicited</td> <td>14.0%</td> <td>22.4%</td> </tr> <tr> <td>SAE, any</td> <td>0.003%</td> <td>0%</td> </tr> </tbody> </table> <p>Proportion of children 5–8 years of age experiencing fever:</p> <table border="1"> <thead> <tr> <th>Outcome</th> <th>Group 1</th> <th>Group 2</th> </tr> </thead> <tbody> <tr> <td>Fever, total</td> <td>8.2%</td> <td>9.2%</td> </tr> <tr> <td>Fever, mild</td> <td>4.1%</td> <td>1.0%</td> </tr> <tr> <td>Fever, moderate</td> <td>2.1%</td> <td>4.1%</td> </tr> <tr> <td>Fever, severe</td> <td>2.1%</td> <td>4.1%</td> </tr> </tbody> </table>	Outcome	Group 1	Group 2	AE, solicited local	70.2%	68.4%	AE, solicited systemic	40.8%	44.9%	AE, unsolicited	14.0%	22.4%	SAE, any	0.003%	0%	Outcome	Group 1	Group 2	Fever, total	8.2%	9.2%	Fever, mild	4.1%	1.0%	Fever, moderate	2.1%	4.1%	Fever, severe	2.1%	4.1%	I	Good Phase IV study that has not been peer- reviewed.
Outcome	Group 1	Group 2																																		
AE, solicited local	70.2%	68.4%																																		
AE, solicited systemic	40.8%	44.9%																																		
AE, unsolicited	14.0%	22.4%																																		
SAE, any	0.003%	0%																																		
Outcome	Group 1	Group 2																																		
Fever, total	8.2%	9.2%																																		
Fever, mild	4.1%	1.0%																																		
Fever, moderate	2.1%	4.1%																																		
Fever, severe	2.1%	4.1%																																		

STUDY DETAILS					SUMMARY																
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality															
				<p>Proportion of children 5–8 years of age experiencing vaccine-related fever:</p> <table border="1"> <thead> <tr> <th>Outcome</th> <th>Group 1</th> <th>Group 2</th> </tr> </thead> <tbody> <tr> <td>Fever, total</td> <td>7.5%</td> <td>5.1%</td> </tr> <tr> <td>Fever, mild</td> <td>4.1%</td> <td>1.0%</td> </tr> <tr> <td>Fever, moderate</td> <td>1.7%</td> <td>4.1%</td> </tr> <tr> <td>Fever, severe</td> <td>1.7%</td> <td>0%</td> </tr> </tbody> </table> <p>The most common local AE was pain. It was not specified whether this pain was associated with the injection site or not. The most common systemic AE was myalgia. A smaller proportion of children in Group 1 appeared to have moderate solicited systemic AE and swelling than children in Group 2.</p>	Outcome	Group 1	Group 2	Fever, total	7.5%	5.1%	Fever, mild	4.1%	1.0%	Fever, moderate	1.7%	4.1%	Fever, severe	1.7%	0%		
Outcome	Group 1	Group 2																			
Fever, total	7.5%	5.1%																			
Fever, mild	4.1%	1.0%																			
Fever, moderate	1.7%	4.1%																			
Fever, severe	1.7%	0%																			
<p>ClinicalTrials.gov <i>A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira Vaccine in Healthy Volunteers.</i> NCT01863433.⁽⁸⁾</p>	<p>Enzira® (Afluria® in other jurisdictions)</p>	<p>RCT England Single-centre 2013–2014 influenza season Sponsored by Seqirus</p>	<p>Healthy adults 18–59 years of age 52.5% female Group 1: 120 adults vaccinated with Enzira® (licensed as Afluria® in other jurisdictions) No control arm</p>	<p>Proportion of adults 18–59 years of age experiencing AE and SAE:</p> <table border="1"> <thead> <tr> <th>Outcome</th> <th>Estimate</th> </tr> </thead> <tbody> <tr> <td>AE, any</td> <td>67.5%</td> </tr> <tr> <td>AE, solicited local</td> <td>52.5%</td> </tr> <tr> <td>AE, solicited systemic</td> <td>19.2%</td> </tr> <tr> <td>AE, unsolicited</td> <td>44.2%</td> </tr> <tr> <td>SAE, any</td> <td>0.0%</td> </tr> </tbody> </table> <p>The most common local AE for adults were pain and injection site pain, and the most common systemic AE was headache.</p>	Outcome	Estimate	AE, any	67.5%	AE, solicited local	52.5%	AE, solicited systemic	19.2%	AE, unsolicited	44.2%	SAE, any	0.0%	I	<p>n/a Phase IV study that has not been peer-reviewed and did not contain a control group.</p>			
Outcome	Estimate																				
AE, any	67.5%																				
AE, solicited local	52.5%																				
AE, solicited systemic	19.2%																				
AE, unsolicited	44.2%																				
SAE, any	0.0%																				

Abbreviations: AE: adverse event; CI: confidence interval; n/a: not applicable; RCT: randomized controlled trial; RR: relative risk; SAE: serious or severe adverse event; TIV: trivalent inactivated influenza vaccine; US: United States

LIST OF ABBREVIATIONS

<i>Abbreviation</i>	<i>Term</i>
AE	Adverse event
CI	Confidence interval
FDA	Food and Drug Administration (United States)
GMFR	Geometric mean fold rise
GMT	Geometric mean titre
HA	Haemagglutinin
HI	Haemagglutination inhibition
IWG	Influenza Working Group
n/a	Not applicable
NACI	National Advisory Committee on Immunization
PHAC	Public Health Agency of Canada
QIV	Quadrivalent inactivated influenza vaccine
RCT	Randomized controlled trial
RNA	Ribonucleic acid
RR	Relative risk
SAE	Serious or severe adverse event
TDOC	Sodium taurodeoxycholate
TIV	Trivalent inactivated influenza vaccine
US	United States

ACKNOWLEDGMENTS

This supplemental statement was prepared by: Ms. K. Young, Dr. L. Zhao, Dr. I. Gemmill, and approved by NACI.

Influenza Working Group Members: Dr. I. Gemmill (Chair), Dr. C. Bancej (CIRID, PHAC), Ms. L. Cochrane, Dr. N. Dayneka, Dr. L. Grohskopf (Centers for Disease Control and Prevention [CDC], United States), Ms. A. Lebens (First Nations and Inuit Health Branch [FNIHB], Indigenous Services Canada [ISC]), Dr. D. Kumar, Dr. J. Langley, Dr. M. Lavoie, Dr. J. McElhaney, Dr. A. McGeer, Dr. D. Moore, Dr. B. Warshawsky, Dr. J. Xiong (Biologics and Genetic Therapies Directorate [BGTD], Health Canada [HC]).

NACI Members: Dr. C. Quach (Chair), Dr. W. Vaudry (Vice-Chair), Dr. N. Dayneka, Dr. S. Deeks, Dr. P. De Wals, Dr. V. Dubey, Dr. R. Harrison, Dr. M. Lavoie, Dr. S. Marchant-Short, Dr. M. Salvadori, Dr. B. Sander, Dr. N. Sicard, Dr. C. Rotstein.

Former NACI Members: Dr. R. Warrington

Liaison Representatives: Dr. J. Brophy (Canadian Association for Immunization Research and Evaluation), Dr. E. Castillo (Society of Obstetricians and Gynaecologist of Canada), Dr. A. Cohn (CDC, United States), Ms. T. Cole (Canadian Immunization Committee), Dr. J. Emili (College of Family Physicians of Canada), Dr. K. Klein (Council of Chief Medical Officers of Health), Dr. C. Mah (Canadian Public Health Association), Dr. D. Moore (Canadian Paediatric Society), Dr. A. Pham-Huy (Association of Medical Microbiology and Infectious Disease Canada).

Ex-Officio Representatives: Dr. (LCdr) K. Barnes (National Defence and the Canadian Armed Forces), Ms. G. Charos (CIRID, PHAC), Dr. R. Pless (BGTD, HC), Dr. J. Gallivan (Marketed Health Products Directorate [MHPD], HC), Mr. G. Poliquin (National Microbiology Laboratory [NML], PHAC), Ms. J. Pennock (CIRID, PHAC), Dr. T. Wong (FNIHB, ISC).

NACI gratefully acknowledges the contribution of Ms. L. Glandon (Healthy Library, HC), Ms. A. House (CIRID, PHAC), Ms. M. Laplante (CIRID, PHAC), and Mr. K. Moncion (CIRID, PHAC).

REFERENCES

1. Schanzer DL, Allison M, Kathleen M. Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada. *Influenza and Other Respiratory Viruses*. 2013;7(5):799-808.
2. Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in Canada, 1992–2009. *PLOS ONE*. 2013;8(11):e80481.
3. Therapeutic Goods Administration (Australian Government). Seasonal Flu Vaccine: Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination [Internet]. 2010. Available from: <https://www.tga.gov.au/alert/seasonal-flu-vaccine-investigation-febrile-reactions-young-children-following-2010-seasonal-trivalent-influenza-vaccination>.
4. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D. Current methods of the US Preventive Services Task Force: A review of the process. *Am J Prev Med*. 2001;20(3):21-35.
5. Seqirus Pty Ltd. Product monograph: AFLURIA® TETRA: Quadrivalent inactivated influenza vaccine (split virion). [Internet]. 2017. Available from: https://pdf.hres.ca/dpd_pm/00043998.PDF.
6. US Food and Drug Administration. Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. [Internet]. 2007. Available from: <https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf>.
7. Treanor JT, Albano FR, Sawlwin DC, Jones AG, Airey J, Formica N, Matassa V, Leong J. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. *Vaccine*. 2017;35(15):1856-64.
8. ClinicalTrials.gov. A study to assess the immunogenicity and safety of a trivalent influenza vaccine containing the 2013/2014 formulation of Enzira vaccine in healthy volunteers. Identifier NCT01863433. [Internet]. 2014. Available from: <https://clinicaltrials.gov/ct2/show/NCT01863433?term=NCT01863433&rank=1>
9. Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, Leong J. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. *Vaccine*. 2017;35(20):2745-52.
10. ClinicalTrials.gov. A study to evaluate the safety and tolerability of trivalent influenza virus vaccine in children aged 5 years to < 9 years. Identifier NCT02212106. [Internet]. 2015. Available from: <https://clinicaltrials.gov/ct2/show/NCT02212106?term=NCT02212106&rank=1>.
11. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, Geelhoed GC, Mascaro F, Scully M, Weeramanthri TS. Epidemiological study of severe febrile reactions in

young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. *BMJ Open*. 2011;1(1):e000016.

12. Rockman S, Becher D, Dyson A, Koernig S, Morelli AB, Barnden M, Camuglia S, Soupourmas P, Pearse M, Maraskovsky E. Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine. *Vaccine*. 2014;32(30):3869-76.

Appendix A: PRISMA flow diagram

Efficacy, effectiveness, immunogenicity, and safety of Afluria® Tetra. August 22, 2017

